Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024

Biophytis announces that it is launching a new clinical development program named OBA, with BIO101 (20- hydroxyecdysone) as a potential treatment for obesity in combination with GLP-1 receptor agonists.